Skip to main content

Critical Care Reviews Newsletter

Newsletter 574  |  December 13th, 2022

Please support our work to share science

Critical Care Reviews Meeting 2023 - The Best Critical Care Trials in the World

Welcome to the 574th Critical Care Reviews Newsletter, bringing you the best critical care research and open access articles from across the medical literature for the week of December 5th to 11th.

The highlights of this week's edition are randomised controlled trials comparing colistin monotherapy with combination therapy for carbapenem-resistant organisms & continuous peripheral nerve blocks for analgesia of ventilated critically ill patients with multiple trauma; a systematic review and meta analysis on awake prone positioning in patients with COVID-19 related hypoxemic respiratory failure; and observational studies on inhaled nitric oxide vs epoprostenol during acute respiratory failure & ECMO for severe accidental hypothermia with cardiac arrest and circulatory instability.

There is also a guideline on hemodynamic monitoring in the critically ill; narrative reviews on in-hospital cardiac arrest & upper gastrointestinal bleeding; editorials on the therapeutic implications of COVID-19's atypical features & terlipressin in patients with acute-on-chronic liver failure; and commentaries on how sepsis parallels and differs from COVID-19 & intravenous fluids in septic shock; as well as correspondence on causal inference and VAP-attributable mortality in COVID-19 & oxygen-free days and the confounders of clinical practice

If you only have time to read one review article this week, try this one on point-of-care ultrasound protocols in the ED and ICU.

CCR23

The Critical Care Reviews Meeting 2023 is on June 14th to 16th, in Titanic Belfast. Join us to hear the results of some of the biggest randomised controlled trials in critical care, as well as review the best trials of the previous 12 months with their chief investigators. It's a very popular meeting, so don't delay in registering if you want to attend.

I hope you find this newsletter useful.


Until next week

Rob